ENTPD1 and neoplasm: Recent research found CXCL13, CD200, and ENTPD1 as unique markers for tumor antigen-specific T cells using scRNA-seq and scTCR-seq. On this basis, developed tumor antigen-specific TCR-T cell therapies have shown significant therapeutic efficacy in autologous patient-derived xenograft (PDX) tumors [208].